Heads up!
We’ve moved some things around. Take a quick tour to learn what has changed.
Take the tour
No thanks!
Xylazine
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Xylazine
- Accession Number
- DB11477
- Description
Xylazine is a clonidine analog which acts as an agonist at α2 adrenoceptors. Veterinarians also use xylazine as an emetic, especially in cats.
- Type
- Small Molecule
- Groups
- Vet approved
- Structure
Structure for Xylazine (DB11477)
- Weight
- Average: 220.33
Monoisotopic: 220.103419697 - Chemical Formula
- C12H16N2S
- Synonyms
- Xilazina
- Xylazinum
- External IDs
- BAY 1470
- WH 7286
Pharmacology
- Indication
- Not Available
- Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More- Pharmacodynamics
- Not Available
- Mechanism of action
Target Actions Organism AAlpha-2 adrenergic receptors agonistHumans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Unlock Additional DataAcebutolol The therapeutic efficacy of Xylazine can be decreased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Aceclofenac is combined with Xylazine. Acemetacin The risk or severity of hypertension can be increased when Xylazine is combined with Acemetacin. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Xylazine. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Xylazine. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Xylazine. Aclidinium Xylazine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Adenosine is combined with Xylazine. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Xylazine. Alclofenac The risk or severity of hypertension can be increased when Xylazine is combined with Alclofenac. Additional Data Available- Extended DescriptionExtended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more - Severity
- Evidence Level
- ActionAction
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more
- Food Interactions
- Not Available
Products
- Product Ingredients
Ingredient UNII CAS InChI Key Xylazine hydrochloride NGC3S0882S 23076-35-9 QYEFBJRXKKSABU-UHFFFAOYSA-N - International/Other Brands
- Anased / Chanazine / Rompun / Sedazine
Categories
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Analgesics
- Central Nervous System Agents
- Central Nervous System Depressants
- Hypnotics and Sedatives
- Muscle Relaxants
- Muscle Relaxants, Centrally Acting Agents
- Neuromuscular Agents
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Sulfur Compounds
- Thiazines
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as m-xylenes. These are aromatic compounds that contain a m-xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups at the 1- and 3-positions.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Xylenes
- Direct Parent
- m-Xylenes
- Alternative Parents
- Aniline and substituted anilines / 1,3-thiazines / Isothioureas / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Aniline or substituted anilines / Aromatic heteromonocyclic compound / Azacycle / Hydrocarbon derivative / Isothiourea / M-xylene / Meta-thiazine / Organic 1,3-dipolar compound / Organic nitrogen compound / Organoheterocyclic compound
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
Chemical Identifiers
- UNII
- 2KFG9TP5V8
- CAS number
- 7361-61-7
- InChI Key
- BPICBUSOMSTKRF-UHFFFAOYSA-N
- InChI
- InChI=1S/C12H16N2S/c1-9-5-3-6-10(2)11(9)14-12-13-7-4-8-15-12/h3,5-6H,4,7-8H2,1-2H3,(H,13,14)
- IUPAC Name
- N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-thiazin-2-amine
- SMILES
- CC1=CC=CC(C)=C1NC1=NCCCS1
References
- General References
- Knight AP: Xylazine. J Am Vet Med Assoc. 1980 Mar 1;176(5):454-5. [PubMed:7358565]
- Beasley M: Xylazine. N Z Vet J. 1995 Jun;43(3):125. [PubMed:16031828]
- Fyffe JJ: Xylazine. N Z Vet J. 1995 Oct;43(5):204-5. [PubMed:16031851]
- Folkers ER: Xylazine precaution. J Am Vet Med Assoc. 1980 May 15;176(10 Pt 1):956. [PubMed:7189750]
- Haskins SC, Patz JD, Farver TB: Xylazine and xylazine-ketamine in dogs. Am J Vet Res. 1986 Mar;47(3):636-41. [PubMed:3963565]
- Haigh JC: Misuse of xylazine. Can Vet J. 1988 Oct;29(10):782-4. [PubMed:17423135]
- Wollen TS: Xylazine and tranquilizers. Mod Vet Pract. 1978 Feb;59(2):80-1. [PubMed:24166]
- Authors unspecified: More comments on xylazine. J Am Vet Med Assoc. 1985 Sep 1;187(5):456-7. [PubMed:4055470]
- Mbiuki SM: Xylazine analgesia in cattle. Vet Med Small Anim Clin. 1981 Oct;76(10):1463-4. [PubMed:6916527]
- Hsu WH: Xylazine-atropine interaction. Am J Vet Res. 1983 May;44(5):928. [PubMed:6870002]
- External Links
- KEGG Drug
- D08683
- ChemSpider
- 5505
- BindingDB
- 50027069
- 1099660
- ChEBI
- 92386
- ChEMBL
- CHEMBL297362
- ZINC
- ZINC000000002248
- Wikipedia
- Xylazine
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.261 mg/mL ALOGPS logP 3.23 ALOGPS logP 3.63 ChemAxon logS -2.9 ALOGPS pKa (Strongest Basic) 6.94 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 24.39 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 68.82 m3·mol-1 ChemAxon Polarizability 24.76 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0229-3920000000-b822873abe0cc77b6500
Targets
- Kind
- Protein group
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Components:
| Name | UniProt ID |
|---|---|
| Alpha-2A adrenergic receptor | P08913 |
| Alpha-2B adrenergic receptor | P18089 |
| Alpha-2C adrenergic receptor | P18825 |
References
- Schwartz DD, Clark TP: Affinity of detomidine, medetomidine and xylazine for alpha-2 adrenergic receptor subtypes. J Vet Pharmacol Ther. 1998 Apr;21(2):107-11. [PubMed:9597647]
Drug created on February 25, 2016 12:05 / Updated on June 12, 2020 10:53
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
![]({"CS-Molecular-Health-1.jpg":"/assets/ads/CS-Molecular-Health-1-19e76f023997d5ac198da2cb9976457f7b9ba733f0ea8a780fe21191c759e8fa.jpg","Drug-Dev-2.jpg":"/assets/ads/Drug-Dev-2-7c3039d93245f493c23278efbf759e4f933848a676262d579087d5cc516af179.jpg","Drug-Search-3.jpg":"/assets/ads/Drug-Search-3-7346c33d2133f62b46cbfbbe2b666e78f955c6847e242692c6081fec37c4d10d.jpg","PM-3.jpg":"/assets/ads/PM-3-13494ac4c996d71619127a11f685681418d4280832dec162c0b2c9c8bc2eda50.jpg","OD-Webinar-1.jpg":"/assets/ads/OD-Webinar-1-f9357f6d57fef5e411aa1c0439ef46c86d9151214434659d096eeed6407b799b.jpg","DDI-3.jpg":"/assets/ads/DDI-3-12808cf864d540ad43757b10b08fc52ae93e793b0c6e81345555187b2840ad09.jpg","EMR-2.jpg":"/assets/ads/EMR-2-adacf8de3f42cb06d6676d06fce611c29781db6ad30776cd18b72a7d8e69f0c8.jpg","Covid.jpg":"/assets/ads/Covid-eed8f17668b0308db62ce3c656f5e2f562376e9185ae08dda5ce6ed9ab0bbd1f.jpg","CS-Molecular-Health-2.jpg":"/assets/ads/CS-Molecular-Health-2-22f41f94b3f87e44a1dcaa8f6c03dc411ab69558efd4f3148ff9bb6adaa956dc.jpg","PM-5.jpg":"/assets/ads/PM-5-d0dc031e0fa0d0097d912eff07b7e80b27b867264dd5b055e379a57bfa2a8723.jpg","DDI-4.jpg":"/assets/ads/DDI-4-313b9c374b937fd78bb2ade652b9b030abb9e6cb90efd35833f793e384e8185b.jpg","Discover-1.jpg":"/assets/ads/Discover-1-b48ae6a3872eeb442f4c22a9a1d867428c83a917ec78a8c3ff4e02f84c5d4fef.jpg","Discover-2.jpg":"/assets/ads/Discover-2-6e7759998ee0fdc234cd84eea962f2480f0c7dafadabd785924918420decb102.jpg","Repurpose-1.jpg":"/assets/ads/Repurpose-1-265fbec40f0eac18d51d3ec4f558c10cb623d834ea75e0296259e458b72ee6d4.jpg","Repurpose-2.jpg":"/assets/ads/Repurpose-2-d12bd1d18b92d36eab60e71e6fd59acf04ef60a53783570e11eef397a0e0f4f5.jpg","PM-6.jpg":"/assets/ads/PM-6-3ae66e41f7ae1e851a0910be89141cf2533509b46df6379464efc885d5ee2f07.jpg","Drug-Search-4.jpg":"/assets/ads/Drug-Search-4-2a9102bd41f16e8c40c9d8044d1dcb6f206ff80107cc269aa83d02ea683bc829.jpg","DDI-5.jpg":"/assets/ads/DDI-5-fa1c287946f4044094c723161577cb5ac631f9cd1217446e510dc79ace6cb94e.jpg","TH-1.jpg":"/assets/ads/TH-1-55a9077bb39e8c38a68c67b555b8091d21a9d41b1c21c7daed3fe53e6f9f3c97.jpg","TH-2.jpg":"/assets/ads/TH-2-1d488747fa4af00ab970a48dba0b228b054d166aa22c1760a310e2b72dd22589.jpg","ThriveHealth-1.jpg":"/assets/ads/ThriveHealth-1-fe42678c71bf2ec7d508fde77efbe9f0aa868c5fa03bd39a7e1c97cefac0fa9d.jpg","ThriveHealth-2.jpg":"/assets/ads/ThriveHealth-2-32bb14bb00de8a1b2efc2a51ce37f490c01e76dac7b9c09b6b831c50640b6567.jpg","ThriveHealth-3.jpg":"/assets/ads/ThriveHealth-3-e184eae1745f8aa22525b294b761ee89f5a854a434d50e5d6d37c0b77f2cf523.jpg","ThriveHealth-4.jpg":"/assets/ads/ThriveHealth-4-218f710e6d20831711d0920e585b986217c38f38d9849b8dd32bb56f68d2eea9.jpg"})
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates